United States - English - NLM (National Library of Medicine)

abbvil chemical llc - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 0.99 kg in 1 kg

United States - English - NLM (National Library of Medicine)

abbvil chemical llc - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 0.99 kg in 1 kg

United States - English - NLM (National Library of Medicine)

abbvil chemical llc - hydrocortisone sodium succinate (unii: 50lqb69s1z) (hydrocortisone sodium succinate - unii:50lqb69s1z) - hydrocortisone sodium succinate 0.98 kg in 1 kg

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium cation - unii:lyr4m0nh37), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 236 g in 274.31 g - gavilyte-g is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults. gavilyte-g is contraindicated in the following conditions: - gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - ileus - hypersensitivity to any component of gavilyte-g [see warnings and precautions (5.8)] animal reproduction studies have not been conducted with gavilyte-g. it is also not known whether gavilyte-g can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte-g should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte-g is administered to a nursing woman. safety and effectiveness of gavilyte-g in pediatric patients have not been established. clinical studies of

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - bisacodyl (unii: 10x0709y6i) (deacetylbisacodyl - unii:r09078e41y) - bisacodyl 5 mg - gavilyte - h and bisacodyl delayed-release tablet, usp is indicated for cleansing of the colon as a preparation for colonoscopy in adults. the gavilyte - h and bisacodyl delayed-release tablet, usp is contraindicated in the following conditions: - gastrointestinal (gi) obstruction - bowel perforation - toxic colitis and toxic megacolon - gastric retention - ileus pregnancy category c animal reproduction studies have not been conducted. it is not known whether gavilyte - h and bisacodyl delayed-release tablet, usp can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte - h and bisacodyl delayed-release tablet, usp should be given to a pregnant or nursing woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte - h and bisacodyl delayed-release tablet, usp is administered to a nursing woman. safety and effectiveness in pediatric patients has

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 236 g in 274.31 g - gavilyte-g is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults. gavilyte-g is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of gavilyte-g [see how supplied/storage and handling (16) ] pregnancy category c. animal reproduction studies have not been conducted with gavilyte-g. it is also not known whether gavilyte-g can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte-g should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte-g is administered to a nursing woman. safety and effectiveness of gavilyte-g in pediatric patients have not been established. clinical studies of gavilyte-g did n

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 420 g in 438.4 g - gavilyte-n is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. gavilyte-n is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of gavilyte-n for oral solution [see how supplied/storage and handling (16)] animal reproduction studies have not been conducted with gavilyte-n. it is also not known whether gavilyte-n can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte-n should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte-n is administered to a nursing woman. safety and effectiveness of gavilyte-n in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of gavilyte-n in adults with additional safety and efficacy data from published studies of similar formulations. use of gavilyte-n in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. dehydration has been reported in one child and hypokalemia has been reported in 3 children. clinical studies of gavilyte-n did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

United States - English - NLM (National Library of Medicine)

thompson medical solutions llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 25 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

United States - English - NLM (National Library of Medicine)

haleon us holdings llc - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - pain reliever/fever reducer - temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis - headache - toothache - backache - menstrual cramps - the common cold - muscular aches - minor pain of arthritis - temporarily reduces fever

United States - English - NLM (National Library of Medicine)

haleon us holdings llc - ibuprofen sodium (unii: rm1ce97z4n) (ibuprofen - unii:wk2xyi10qm) - pain reliever/fever reducer